|Bid||2.5300 x 1100|
|Ask||2.6500 x 800|
|Day's Range||2.5300 - 2.7400|
|52 Week Range||0.2310 - 7.0300|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 31, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
Genprex adds two accomplished life science leaders to its executive team.
Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases. Genprex's technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and other serious diseases who currently have limited treatment options.
Benzinga Pro's Stocks To Watch For Wednesday Bellerophon (BLPH) - Following a nearly 170% rally to close Tuesday's session, Bellerophon shares pulled back about 5% to under the $9 level Wednesday morning. ...
While adding money to the balance sheet is seldom a negative, the impact it can have on shareholders or the stock price can absolutely create a negative overhang sometimes lasting for months, if not longer. It's easy to find examples of a "bad" capital raise as well as a good capital raise, but it is seldom you see both from the same company within a two month span, but that's exactly what we got with Genprex .
Shares of Genprex Inc. climbed 53% in morning trading on Wednesday after the company said the Food and Drug Administration had granted its experimental cancer treatment a fast-track designation. Genprex is testing the therapy in combination with AstraZeneca's Tagrisso for certain non-small cell lung cancer patients. AstraZeneca said in October that Tagrisso brought in $2.3 billion in sales year-to-date, an 82% jump compared to the year prior. Its stock was up 0.7% on Wednesday. Genprex plans to start a Phase I/II clinical trial for the investigational combination treatment. Genprex's stock is up 12% over the past year, while the S&P 500 has gained 24%.
AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16 th , 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, ...
Treatment for breast cancer varies, based on both the patient’s circumstances and type of cancer. The development of treatments to suppress or even eliminate cancer has led to a high survival rate in wealthy countries, with around 85% of patients in the United States and United Kingdom surviving for at least five years from diagnosis. Cancer is a difficult disease to defeat, and survival can depend upon the ability of scientists to counter a specific genetic defect in a specific set of cells.
NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. Advances in biotechnology look to deliver promising new treatment options against breast cancer. Breast cancer is one of the most widely prevalent cancers in the world.
Imagined in the 1970s and first carried out in the 1980s, gene therapy is one of the newest frontiers in medicine. A number of companies have emerged with the aim of applying gene therapy to specific diseases. For example, Genprex Inc. (GNPX) specializes in tackling non-small cell lung cancer through its developmental drug Oncoprex(TM).
NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (GNPX) announces the availability of an audio press release broadcast titled, “Record Revenues, Milestone Achievements Indicate Strength, Potential of Biotech Sector” and produced by NetworkNewsWire (“NNW”). With significant milestones being met, Genprex Inc. (GNPX) is pressing forward with its strategy objectives to reprogram the course of cancer. The company plans on continuing to conduct ongoing and new clinical trials as well as pursue strategic partnerships with organizations whose missions align with its own.
NEW YORK, Aug. 22, 2019 -- via NetworkWire -- Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.
Preliminary results show that Oncoprex has the potential to become an effective add-on therapy for the treatment of deadly non-small cell lung cancer. Genprex Inc. (GNPX) plans to expand the current erlotinib-Oncoprex trial to multiple research centers and conduct more new trials. If Phase II results are as positive as preliminary indications, it could spark a rally in the shares and possibly even lure a large biotechnology or pharma company to sign a high-value partnership with Genprex.
NEW YORK, May 30, 2019 -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.
Gene therapies, the promising treatments pursued by companies such as Genprex Inc. (GNPX), are based on turning [the] problem [of cell mutation] on its head. Once in place, successful gene therapies replace damaged or missing code and help the body cure itself. Creating these treatments is challenging work, and the companies that excel are innovators with the ability to try new approaches.